Genomic Profiling of Breast Cancer Brain Metastases
Author Information
Author(s): Giannoudis A., Sokol E. S., Bhogal T., Ramkissoon S. H., Razis E. D., Bartsch R., Shaw J. A., McGregor K., Clark Alison, Huang R.S.P., Palmieri C.
Primary Institution: Foundation Medicine, Inc.
Hypothesis
Understanding the genomic landscape of breast cancer brain metastases (BCBMs) is key to developing targeted treatments.
Conclusion
A high proportion of BCBMs are potentially treatable with targeted therapies, including PARP inhibitors and immune checkpoint inhibitors.
Supporting Evidence
- Clinically relevant genomic alterations were significantly enriched in BCBMs compared to local breast cancers and non-CNS metastases.
- High PD-L1 protein expression was observed in ER-negative/HER2-negative BCBMs.
- Homologous recombination deficiency was more prevalent in BCBMs than in local breast cancers and N-CNS metastases.
Takeaway
This study looked at the genes in breast cancer that spread to the brain and found many that could be targeted with new medicines.
Methodology
Genomic profiling was performed on 822 BCBMs, 11,988 local breast cancer biopsies, and 15,516 non-central nervous system metastases using next-generation sequencing.
Potential Biases
Bias may arise from the profiling process, as cases had to be sent for profiling, potentially influenced by funding access and healthcare team willingness.
Limitations
The study lacks paired primary and non-CNS metastatic tissue, which could provide additional insights into disease evolution.
Participant Demographics
The study included patients with breast cancer brain metastases, but specific demographic details were not provided.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website